



## Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: [www.bioscmed.com](http://www.bioscmed.com)

# Profound Immunosuppression with Reversed CD4:CD8 Ratio in a Tuberculosis Patient with Acquired Immunodeficiency Syndrome: A Case Report

Doan Atrya<sup>1</sup>, Efrida<sup>2\*</sup>

<sup>1</sup>Faculty of Medicine, Universitas Andalas, Padang, Indonesia

<sup>2</sup>Dr. M. Djamil General Hospital, Padang, Indonesia

### ARTICLE INFO

#### Keywords:

AIDS

CD4/CD8 ratio

HIV

Immunosuppression

Tuberculosis

#### \*Corresponding author:

Efrida

#### E-mail address:

[efrida@med.unand.ac.id](mailto:efrida@med.unand.ac.id)

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/bsm.v9i3.1227>

### ABSTRACT

**Background:** The co-occurrence of tuberculosis (TB) and acquired immunodeficiency syndrome (AIDS) presents a formidable clinical challenge due to the synergistic impact on the immune system. This case report describes a patient with TB/AIDS co-infection exhibiting profound immunosuppression characterized by a severely diminished CD4 count and an unusual reversal of the CD4:CD8 ratio. **Case presentation:** A 39-year-old male presented with symptoms indicative of both TB and advanced HIV infection, including shortness of breath, weight loss, and oral thrush. Physical examination revealed bilateral lung crackles. Laboratory investigations confirmed pulmonary TB and revealed a critically low CD4 count (6 cells/ $\mu$ L), and a CD8 count of 71 cells/ $\mu$ L, resulting in a reversed CD4:CD8 ratio of 0.08. The patient's HIV viral load was markedly elevated at 598,403 copies/mL. This case underscores the complex interplay between TB and HIV, highlighting the profound impact of co-infection on immune system function. The patient's severely depleted CD4 count and the atypical CD4:CD8 ratio reflect the advanced stage of HIV infection and the superimposed TB. The findings emphasize the need for close monitoring and aggressive management of co-infected patients to mitigate the risk of opportunistic infections and disease progression. **Conclusion:** This case report documents a rare and severe presentation of TB/AIDS co-infection with profound immunosuppression and a reversed CD4:CD8 ratio. It serves as a reminder of the significant morbidity and mortality associated with advanced HIV and TB co-infection, particularly in cases of delayed diagnosis or suboptimal treatment adherence.

## 1. Introduction

Tuberculosis (TB), an infectious disease primarily caused by the bacterium *Mycobacterium tuberculosis*, continues to pose a significant global health challenge. Characterized predominantly by pulmonary manifestations, TB remains a leading cause of morbidity and mortality worldwide, particularly in resource-limited settings. The World Health Organization (WHO) estimates that approximately 10.6 million people will fall ill with TB in 2021, underscoring the persistent burden of this disease. The global fight against TB is further complicated by the Human Immunodeficiency Virus (HIV) pandemic.

HIV, the causative agent of acquired immunodeficiency syndrome (AIDS), profoundly weakens the immune system, rendering individuals highly susceptible to opportunistic infections, including TB. The synergy between TB and HIV creates a syndemic, with each disease exacerbating the progression and severity of the other. TB is a leading cause of death among people living with HIV (PLWH), and HIV infection dramatically increases the risk of latent TB infection progressing to active TB disease. The interaction between TB and HIV is complex and multifactorial. HIV targets and destroys CD4<sup>+</sup> T lymphocytes (T helper cells), which play a critical role

in orchestrating the immune response against *Mycobacterium tuberculosis*. The depletion of CD4+ T cells impairs the host's ability to control the replication of the bacteria, facilitating the development of active TB disease. Furthermore, HIV infection can alter the clinical presentation of TB, making diagnosis more challenging. In advanced HIV disease, TB may present atypically, with extrapulmonary involvement or disseminated disease more common than in HIV-negative individuals.<sup>1-4</sup>

The diagnosis of TB in PLWH relies on a combination of clinical, radiological, and microbiological investigations. However, traditional diagnostic methods, such as sputum smear microscopy and culture, may have limitations in this population, particularly in individuals with advanced HIV disease who may have difficulty producing sputum or present with paucibacillary disease. Newer diagnostic tools, such as Xpert MTB/RIF, offer improved sensitivity and the ability to detect rifampicin resistance, a critical factor in guiding treatment decisions. Immunological monitoring, particularly of CD4+ T lymphocyte counts, is essential in the management of HIV infection. The absolute CD4 count and the CD4:CD8 ratio provide valuable insights into the level of immunosuppression and the risk of opportunistic infections. A CD4 count below 200 cells/ $\mu$ L is a defining criterion for the diagnosis of AIDS and indicates a significantly increased risk of TB and other opportunistic infections. The CD4:CD8 ratio, a measure of the balance between T helper cells and cytotoxic T cells, can also serve as a prognostic indicator of HIV infection. A ratio less than 1 is associated with advanced HIV disease and heightened susceptibility to opportunistic infections.<sup>5-7</sup>

Antiretroviral therapy (ART) has revolutionized the management of HIV infection, dramatically improving the quality of life and life expectancy of PLWH. ART suppresses HIV replication, leading to a restoration of the immune system and a reduction in the risk of opportunistic infections, including TB. Early initiation of ART is crucial in preventing TB disease in PLWH, and prompt treatment of TB is essential in improving

outcomes in co-infected individuals. The management of TB/HIV co-infection requires a comprehensive approach that addresses both diseases. This includes the prompt diagnosis and treatment of both TB and HIV, the provision of ART to all co-infected individuals, and the prevention of TB in PLWH through targeted screening and preventive therapy. Close monitoring for drug interactions and adverse events is also crucial, as the treatment regimens for TB and HIV can be complex and have overlapping toxicities.<sup>8-10</sup> This case report presents a patient with TB/AIDS co-infection exhibiting profound immunosuppression with a severely reduced CD4 count and a reversed CD4:CD8 ratio.

## 2. Case Presentation

This report details the case of a 39-year-old male who presented to the hospital with a constellation of symptoms suggestive of both tuberculosis (TB) and advanced HIV infection. The patient's clinical presentation, along with the subsequent laboratory and imaging investigations, revealed a complex interplay between these two diseases, highlighting the profound impact of co-infection on immune system function. The patient's medical history was significant for HIV infection, diagnosed in 2008. Unfortunately, his adherence to antiretroviral therapy (ART) was suboptimal, with a 3-year interruption in treatment. Although he had resumed ART 2 months prior to this presentation, this gap in treatment likely contributed to the progression of his HIV disease and increased his susceptibility to opportunistic infections, such as TB. The patient's presenting complaints included progressive shortness of breath for 7 days, a productive cough for 1 week, and low-grade intermittent fever for the same duration. These symptoms are classic indicators of pulmonary TB, suggesting active infection and potential respiratory compromise. Additionally, the patient reported a 10 kg weight loss over the preceding 6 months and oral thrush for 1 month, both of which are concerning signs in the context of HIV infection. Weight loss can be a consequence of both TB and HIV, reflecting the

catabolic effects of these diseases and potential malabsorption. Oral thrush, caused by the opportunistic fungus *Candida albicans*, is a common manifestation of immune deficiency in HIV-infected individuals. The patient's history of high-risk behaviors, although ceased after his HIV diagnosis, likely played a role in his initial acquisition of HIV. This underscores the importance of ongoing education and counseling regarding safe sexual practices and harm reduction strategies, even after an HIV diagnosis. On physical examination, the patient appeared unwell and exhibited signs of respiratory distress. His respiratory rate was elevated at 24 breaths per minute, indicating tachypnea, a common finding in pulmonary infections. Oral thrush, as reported by the patient, was confirmed on examination, further suggesting immune suppression. Lung auscultation revealed increased tactile fremitus on the left compared to the right, suggesting consolidation or increased density in the left lung. Bronchovesicular breath sounds were noted, which can be a normal finding but may also indicate underlying lung pathology. Bilateral rales, or crackling sounds heard during inspiration, were also present, suggesting the presence of fluid or secretions in the airways. These findings, in conjunction with the patient's respiratory symptoms, pointed towards a pulmonary infection, likely TB. Laboratory investigations were crucial in confirming the diagnosis and assessing the severity of the patient's condition. Sputum examination, a cornerstone of TB diagnosis, revealed acid-fast bacilli (AFB) on smear microscopy, indicating the presence of mycobacteria. The smear was graded as 3+, signifying a high bacillary load, which is associated with increased infectivity and disease severity. Sputum culture, the gold standard for TB diagnosis, confirmed the presence of *Mycobacterium tuberculosis* complex, further solidifying the diagnosis of pulmonary TB. Xpert MTB/RIF testing, a rapid molecular diagnostic tool, was also performed. This test not only detects *Mycobacterium tuberculosis* complex but also identifies rifampicin resistance, a critical factor in

guiding treatment decisions. In this case, the Xpert MTB/RIF assay confirmed the presence of *Mycobacterium tuberculosis* complex and, importantly, indicated that the strain was sensitive to rifampicin, allowing for the initiation of standard first-line TB treatment. Immunological testing revealed a critically low absolute CD4 count of 6 cells/ $\mu$ L, far below the threshold of 200 cells/ $\mu$ L that defines AIDS. This profound immunosuppression explained the patient's susceptibility to TB and the severity of his presentation. The HIV viral load was markedly elevated at 598,403 copies/mL, indicating uncontrolled HIV replication and further contributing to the immune deficiency. Chest radiography provided visual evidence of the pulmonary involvement in this case. The X-ray revealed bilateral infiltrates with cavitation in the upper lobes, a characteristic finding in pulmonary TB. Cavitation, the formation of cavities within the lung tissue, reflects the destructive nature of TB and can contribute to the spread of the bacteria. The right lung showed more extensive infiltrates compared to the left lung, suggesting a greater burden of disease on that side. Based on the comprehensive clinical, laboratory, and imaging findings, the patient was diagnosed with; Tuberculosis (TB): The presence of respiratory symptoms, positive sputum smear and culture for *Mycobacterium tuberculosis* complex, and characteristic chest X-ray findings confirmed the diagnosis of pulmonary TB; Acquired Immunodeficiency Syndrome (AIDS): The patient's severely depleted CD4 count (6 cells/ $\mu$ L) and the clinical manifestations of opportunistic infections, such as oral thrush, met the criteria for the diagnosis of AIDS; Stage III HIV infection: According to the WHO clinical staging system for HIV infection, the patient's CD4 count and clinical presentation placed him in Stage III, the most advanced stage of HIV disease, characterized by severe immunosuppression and a high risk of opportunistic infections. This case highlights the complex interplay between TB and HIV, underscoring the importance of early diagnosis, prompt treatment, and close monitoring in co-infected individuals. The patient's profound

immunosuppression, evidenced by the critically low CD4 count and reversed CD4:CD8 ratio, emphasizes the need for comprehensive care that addresses both TB and HIV to improve clinical outcomes (Table 1).

Immunological testing played a crucial role in this case, providing critical insights into the patient's immune status and the severity of his HIV infection. These tests, primarily focused on T lymphocyte subsets and HIV viral load, revealed a profound state of immunosuppression, which significantly contributed to the patient's susceptibility to TB and the severity of his clinical presentation. CD4+ T lymphocytes, also known as T helper cells, are essential components of the adaptive immune system. They orchestrate the immune response against various pathogens, including *Mycobacterium tuberculosis*, by activating other immune cells and secreting cytokines that regulate immune function. HIV specifically targets and destroys CD4+ T cells, leading to a progressive decline in their numbers and a corresponding weakening of the immune system. In this case, the patient's absolute CD4 count was critically low at 6 cells/ $\mu$ L, far below the normal range of 404-1,612 cells/ $\mu$ L. This severe depletion of CD4+ T cells indicated a profound state of immunosuppression, rendering the patient highly vulnerable to opportunistic infections, including TB. The CD4 count is a key indicator of immune function in HIV-infected individuals and is used to monitor disease progression, guide treatment decisions, and predict the risk of opportunistic infections. The CD4 percentage, which represents the proportion of CD4+ T cells among all lymphocytes, was also markedly reduced at 5.1%. This further confirmed the significant loss of CD4+ T cells and the severity of the patient's immune deficiency. CD8+ T lymphocytes, or cytotoxic T cells, are another important subset of T cells involved in cell-mediated immunity. They play a crucial role in recognizing and destroying infected cells, contributing to the control of intracellular pathogens like *Mycobacterium tuberculosis*. While HIV primarily targets CD4+ T cells, it can also indirectly affect CD8+ T cell function. In this case, the patient's

absolute CD8 count was 71 cells/ $\mu$ L, which falls within the lower end of the normal range (220-1,129 cells/ $\mu$ L). However, the CD8 percentage was elevated at 63.6%, reflecting a relative increase in CD8+ T cells compared to CD4+ T cells. This imbalance in T cell subsets is a common finding in HIV infection and can further contribute to immune dysregulation. The CD4:CD8 ratio is a valuable indicator of immune system balance and can provide prognostic information in HIV infection. A normal CD4:CD8 ratio is typically between 0.69 and 2.83, reflecting the predominance of CD4+ T helper cells over CD8+ cytotoxic T cells. However, in HIV infection, as CD4+ T cells are depleted, this ratio can become inverted, with CD8+ T cells outnumbering CD4+ T cells. In this case, the patient's CD4:CD8 ratio was severely reversed at 0.08, indicating a significant imbalance in T cell subsets and reflecting the advanced stage of his HIV disease. A reversed CD4:CD8 ratio has been associated with increased susceptibility to opportunistic infections, poorer immune recovery on ART, and accelerated disease progression. HIV viral load, a measure of the amount of HIV in the blood, is a crucial marker of HIV disease activity and treatment response. A high viral load indicates active viral replication and ongoing damage to the immune system. In this case, the patient's HIV viral load was markedly elevated at 598,403 copies/mL, signifying uncontrolled HIV replication and contributing to the profound immunosuppression. The high viral load also highlights the importance of adherence to ART in suppressing viral replication and restoring immune function. The immunological parameters in this case were assessed using flow cytometry with immunophenotyping. This technique allows for the identification and quantification of different cell populations based on their surface markers. It is a highly sensitive and specific method for analyzing lymphocyte subsets and is widely used in clinical practice for monitoring HIV infection. The immunological findings in this case paint a clear picture of severe immune deficiency, driven by uncontrolled HIV replication and profound CD4+ T cell

depletion. This immunosuppression significantly contributed to the patient's susceptibility to TB, the severity of his clinical presentation, and the challenges in managing his condition. These findings underscore

the critical importance of early diagnosis and treatment of HIV infection, as well as adherence to ART, in preventing opportunistic infections and improving clinical outcomes (Table 2).

Table 1. Anamnesis, clinical finding, laboratory, imaging, and clinical diagnosis.

Category	Specific findings
<b>Anamnesis</b>	* a 39-year-old male with Progressive shortness of breath for 7 days
	* 10 kg weight loss over 6 months
	* Oral thrush for 1 month
	* Low-grade intermittent fever for 1 week
	* Productive cough for 1 week
	* History of HIV infection since 2008
	* 3-year interruption in antiretroviral therapy
	* Resumption of antiretroviral therapy 2 months prior
	* History of high-risk behaviors (ceased after HIV diagnosis)
<b>Clinical findings</b>	* Respiratory rate: 24 breaths per minute
	* Oral thrush
	* Lung examination: Increased tactile fremitus on the left compared to the right
	* Lung examination: Bronchovesicular breath sounds
	* Lung examination: Bilateral rales
<b>Laboratory</b>	* Sputum Examination:
	* Acid-Fast Bacilli (AFB) smear: Positive (3+)
	* Sputum culture: Growth of Mycobacterium tuberculosis complex
	* Xpert MTB-RIF Testing:
	* Detection of Mycobacterium tuberculosis complex: Positive
	* Rifampicin resistance: Not detected (sensitive)
	* Immunological Testing:
	* Absolute CD4 count: 6 cells/ $\mu$ L
<b>Imaging</b>	* HIV Viral Load: 598,403 copies/mL
	* Chest X-ray:
	* Bilateral infiltrates with cavitation in the upper lobes
	* Right lung: More extensive infiltrates compared to the left lung
<b>Clinical diagnosis</b>	* Tuberculosis (TB)
	* Acquired Immunodeficiency Syndrome (AIDS)
	* Stage III HIV infection (based on CD4 count and clinical presentation)

Table 2. Immunological testing.

Parameter	Results	Unit	Reference value	Method
<b>CD4</b>				
Absolute CD4 Count	6	cell/uL	404-1,612	Flow cytometry with Immunophenotyping
CD4%	5,1	%	33-58	Calculation
<b>CD8</b>				
Absolute CD8 Count	71	cell/uL	220-1,129	Flow cytometry with Immunophenotyping
CD8%	63,6	%	13-39	Calculation
<b>CD4:CD8 Ratio</b>	0.08	-	0,69-2,83	Calculation
<b>HIV Viral Load</b>	598,403	copies/mL	Not detected	Real-Time PCR

### 3. Discussion

The patient's clinical picture is indeed a stark representation of the detrimental synergy between TB and HIV. These two pathogens, formidable on their own, form a devastating alliance when they co-exist within a host. This synergy cripples the immune system, leaving the individual highly vulnerable to a cascade of complications and significantly increasing the risk of severe disease. To understand this synergy, we need to delve into the intricate workings of the immune system and how HIV disrupts its delicate balance. HIV, a retrovirus, specifically targets CD4+ T lymphocytes, also known as T helper cells. These cells are essential for a well-functioning immune system. They act as the "command center," orchestrating the complex network of cellular interactions and signaling pathways that are crucial for recognizing and eradicating invading pathogens. Imagine the immune system as a well-coordinated army. The CD4+ T cells are the generals, responsible for strategizing and directing the troops (other immune cells) to fight off the enemy (pathogens). When HIV attacks and destroys these generals, the army is left disorganized and vulnerable, unable to mount an effective defense. In the context of TB, CD4+ T cells play an indispensable role. When *Mycobacterium tuberculosis*, the bacterium responsible for TB, enters the lungs, it is engulfed by macrophages, a type of white blood cell that acts as the first line of defense. However, *M. tuberculosis* is a cunning adversary, capable of surviving and even replicating within these macrophages. This is where CD4+ T cells step in. They recognize infected macrophages and release signaling molecules called cytokines, which activate the macrophages, enhancing their ability to kill the intracellular bacteria. In essence, CD4+ T cells act as the "reinforcements," providing the macrophages with the necessary firepower to effectively combat the TB infection. HIV, by progressively destroying CD4+ T cells, weakens this critical line of defense, creating an environment where *M. tuberculosis* can thrive. The depletion of CD4+ T cells impairs the activation of macrophages, hindering their ability to control the

replication of the bacteria. This allows *M. tuberculosis* to establish a foothold in the lungs and potentially spread to other parts of the body, leading to active TB disease. In this case, the patient's severely diminished CD4 count of 6 cells/ $\mu$ L is a testament to the advanced stage of his HIV infection and the profound state of immunosuppression. This degree of immune deficiency rendered him highly susceptible to opportunistic infections, with TB being a leading cause of morbidity and mortality among individuals with advanced HIV disease. Moreover, the presence of TB further exacerbates the immune dysfunction. The inflammatory response triggered by the TB infection can accelerate the destruction of CD4+ T cells, contributing to a vicious cycle of immune decline. This highlights the synergistic nature of TB/HIV co-infection, where each disease amplifies the detrimental effects of the other. The synergistic impact of TB and HIV on the immune system has far-reaching clinical implications. Individuals with TB/HIV co-infection are at increased risk of developing severe forms of TB, including disseminated disease and extrapulmonary TB. They are also more likely to experience treatment failure and relapse, as their weakened immune systems struggle to control the infection. This case underscores the critical importance of early diagnosis and treatment of both TB and HIV. Antiretroviral therapy (ART), which suppresses HIV replication and helps restore immune function, is crucial in preventing the progression of HIV disease and reducing the risk of opportunistic infections, including TB. Similarly, prompt and effective treatment of TB is essential in preventing further immune decline and improving clinical outcomes in co-infected individuals. The synergy between TB and HIV extends beyond the individual level, posing significant challenges to public health efforts to control both diseases. In areas with high prevalence of both infections, TB/HIV co-infection can strain healthcare resources and hinder progress towards achieving global targets for TB and HIV elimination. This case highlights the urgent need for integrated TB/HIV care and prevention strategies.

Ensuring access to early diagnosis and treatment for both TB and HIV, particularly in resource-limited settings. Providing support and counseling to improve adherence to ART, which is crucial for preventing opportunistic infections and improving treatment outcomes. Screening high-risk populations for both TB and HIV to identify co-infected individuals and initiate prompt treatment. Educating the public about the risks of TB/HIV co-infection and promoting preventive measures, such as safe sex practices and vaccination against TB (where available).<sup>11,12</sup>

A striking finding in this case is the severely reversed CD4:CD8 ratio of 0.08. This stark deviation from the normal range serves as a grim indicator of the profound immune dysfunction affecting the patient. It's a red flag that highlights the complex interplay between HIV and TB, and underscores the need for aggressive management to mitigate the risk of further complications. The CD4:CD8 ratio is a crucial measure of the balance within the immune system, particularly in individuals with HIV. It reflects the relative proportion of two key players in the immune response: CD4+ and CD8+ T lymphocytes. CD4+ T cells (Helper T cells) are the orchestrators, the conductors of the immune symphony. They don't directly kill pathogens, but they are essential for initiating and coordinating the immune response. They activate other immune cells, such as macrophages and B cells, and release signaling molecules called cytokines that guide the immune response. Think of them as the generals who strategize and direct the troops. CD8+ T cells (Cytotoxic T cells) are the front-line soldiers, the assassins of the immune system. They directly kill infected cells, eliminating threats like viruses, intracellular bacteria, and cancer cells. They are crucial for controlling infections and preventing the spread of disease. In a healthy individual, the CD4:CD8 ratio is typically greater than 1, reflecting a predominance of CD4+ T cells. This ensures a well-coordinated and effective immune response against a wide range of pathogens. HIV, however, disrupts this delicate balance. The virus specifically targets and destroys CD4+ T cells, leading

to a progressive decline in their numbers and a corresponding decrease in the CD4:CD8 ratio. As this ratio falls below 1, it signifies a state of immune deficiency, where the body's ability to fight infections is significantly compromised. In this case, the patient's CD4:CD8 ratio of 0.08 is not just low, it is severely reversed. This indicates a more profound immune dysfunction than might be suggested by the CD4 count alone. While a low CD4 count reflects the loss of helper T cells, a reversed CD4:CD8 ratio suggests a broader dysregulation of the immune system, potentially involving both T cell subsets. Although HIV primarily targets CD4+ T cells, it can also indirectly affect CD8+ T cell function. This can manifest as decreased cytotoxic activity, impaired proliferation, and increased susceptibility to apoptosis (programmed cell death). Essentially, the virus not only decimates the generals but also weakens the soldiers. HIV infection triggers a state of chronic immune activation and inflammation. This ongoing "battle" within the immune system can disrupt the delicate balance between T cell subsets and contribute to immune dysfunction. Imagine a constant state of alert, where the immune system is perpetually on edge, leading to exhaustion and disarray. The presence of TB further complicates the picture. The inflammatory response to TB infection can accelerate the destruction of CD4+ T cells and contribute to the overall immune decline, further skewing the CD4:CD8 ratio. It's like adding fuel to the fire, intensifying the immune dysregulation. Studies have consistently shown that a reversed CD4:CD8 ratio in HIV-infected individuals is associated with a constellation of adverse outcomes. The severely compromised immune system is like a city with weakened defenses, vulnerable to opportunistic invaders. This leads to a higher risk of infections like TB, Pneumocystis pneumonia (PCP), cryptococcal meningitis, and others, which can be life-threatening in individuals with weakened immune systems. Even with the advent of antiretroviral therapy (ART), which has revolutionized the treatment of HIV, individuals with a reversed CD4:CD8 ratio may experience slower and

less complete immune reconstitution. This means that even with treatment, their immune system may not fully recover, hindering their ability to fight off infections and increasing their susceptibility to future health complications. A reversed CD4:CD8 ratio can be a harbinger of more rapid progression to AIDS and an increased risk of AIDS-related complications. It's a sign that the virus is gaining ground and the immune system is losing the battle. This finding in our patient underscores the severity of his immune deficiency and the need for aggressive management to mitigate the risk of further complications. It's a call to action, urging healthcare providers to take a proactive and comprehensive approach to his care. Ensuring adherence to ART is paramount. ART suppresses HIV replication and helps restore immune function, but its effectiveness hinges on consistent and lifelong adherence. Healthcare providers need to work closely with patients to address any barriers to adherence and ensure they are taking their medications as prescribed. In individuals with severely compromised immune systems, preventive therapy for common opportunistic infections, such as PCP and toxoplasmosis, may be necessary to reduce the risk of these complications. It's like reinforcing the city walls to prevent opportunistic invaders from breaching the defenses. Vigilant monitoring is crucial. Healthcare providers need to closely monitor the patient for any signs of opportunistic infections or disease progression, with prompt intervention as needed. It's like having vigilant guards on the watchtowers, ready to sound the alarm at the first sign of trouble. Managing any other underlying health conditions that may further compromise the immune system or complicate treatment is essential. This includes conditions like diabetes, hypertension, and mental health disorders. It's like ensuring that all aspects of the city's infrastructure are functioning optimally to support the defenses.<sup>13-15</sup>

The patient's history of suboptimal adherence to antiretroviral therapy (ART) emerges as a critical factor in the progression of his HIV disease and the development of opportunistic infections, most notably

TB. This case serves as a stark reminder of the indispensable role of ART adherence in managing HIV infection and preventing the cascade of complications that can arise from uncontrolled viral replication and immune deficiency. ART has revolutionized the landscape of HIV care, transforming what was once a deadly disease into a manageable chronic condition. By effectively suppressing HIV replication, ART offers a lifeline to individuals living with HIV, enabling them to lead longer, healthier lives. By keeping HIV replication in check, ART helps maintain a healthy population of CD4+ T cells, the vital orchestrators of the immune response. This, in turn, strengthens the body's ability to fight off infections and prevents the development of opportunistic diseases. ART significantly reduces the risk of opportunistic infections, such as TB, *Pneumocystis pneumonia* (PCP), and cryptococcal meningitis, which are major causes of morbidity and mortality in individuals with advanced HIV disease. ART not only benefits the individual taking the medication but also has a profound impact on public health. By suppressing viral load to undetectable levels, ART dramatically reduces the risk of HIV transmission to sexual partners. This has contributed significantly to the global effort to control the HIV epidemic. However, the effectiveness of ART hinges on a critical factor: adherence. Consistent and lifelong adherence to the prescribed ART regimen is essential to reap the full benefits of this life-saving therapy. When ART adherence falters, HIV can seize the opportunity to resurge, leading to virological failure. This is characterized by a rebound in HIV viral load and a decline in CD4 count, signaling a weakening of the immune system and an increased risk of opportunistic infections. Imagine a fortress where the defenses have been weakened, opportunistic invaders are more likely to breach the walls and cause harm. Interruptions in ART can create a breeding ground for drug-resistant HIV strains. These strains are more difficult to treat, as they may not respond to standard ART regimens, requiring the use of more complex and potentially toxic medications. It's like a battle where the enemy



adapts and becomes resistant to the weapons used against it, making the fight even more challenging. Non-adherence can accelerate the progression of HIV disease, leading to a more rapid decline in immune function and an increased risk of developing AIDS-related complications. This can have a devastating impact on the individual's health and quality of life. In the case presented, the patient's 3-year interruption in ART likely played a pivotal role in the uncontrolled HIV replication, as evidenced by the high viral load of 598,403 copies/mL. This prolonged period of non-adherence allowed the virus to regain its foothold, decimating the CD4+ T cell population and rendering the patient highly susceptible to opportunistic infections, including TB. While the resumption of ART 2 months prior to presentation was a positive step, the delay in treatment likely allowed for significant immune damage and the establishment of TB infection. This underscores the importance of early and consistent ART adherence in preventing the progression of HIV disease and the development of opportunistic infections. Achieving optimal ART adherence is a complex challenge that requires a multifaceted approach. Healthcare providers must go beyond simply prescribing medications, they must actively engage with patients, understand their individual needs and challenges, and provide ongoing support to foster adherence. Providing clear and comprehensive information about the benefits of ART and the consequences of non-adherence is crucial. Patients need to understand that ART is a lifelong commitment and that adherence is essential for their health and well-being. It's like educating soldiers about the importance of their mission and the consequences of failing to follow orders. Identifying and addressing individual barriers to adherence is essential. These barriers can be diverse, ranging from medication side effects and pill fatigue to social and economic challenges, such as stigma, poverty, and lack of access to healthcare. It's like identifying and removing obstacles that hinder the soldiers' ability to reach their destination and complete their mission. Whenever possible, simplifying treatment regimens

can improve adherence. This may involve reducing the number of pills or the frequency of dosing, or using fixed-dose combinations to make it easier for patients to take their medications correctly. It's like streamlining the soldiers' equipment and supplies to make their journey less burdensome. Technology can play a supportive role in promoting adherence. This can include mobile phone apps that send medication reminders, electronic pillboxes that track medication usage, and telehealth platforms that facilitate remote monitoring and support. It's like providing the soldiers with advanced tools and communication systems to enhance their effectiveness and safety. A trusting and supportive relationship between the patient and the healthcare provider is essential for fostering adherence. Open communication, empathy, and shared decision-making can empower patients to take an active role in their care and improve their adherence to ART. It's like fostering a strong bond between the generals and the soldiers, built on trust, respect, and mutual understanding.<sup>16-18</sup>

Diagnosing tuberculosis (TB) in individuals infected with the human immunodeficiency virus (HIV) is like navigating a complex maze. The interplay between these two diseases creates a web of diagnostic challenges, demanding a high index of suspicion, a comprehensive approach to evaluation, and the judicious use of diagnostic tools. In HIV-infected individuals, TB often deviates from its typical script, manifesting with atypical symptoms or signs that can easily mislead even the most astute clinician. This is because HIV, by weakening the immune system, alters the body's response to TB infection, leading to a diverse array of clinical presentations. While pulmonary TB, affecting the lungs, is the most common form of the disease, extrapulmonary TB, which involves organs other than the lungs, is more prevalent in HIV-infected individuals. This can involve lymph nodes, pleura (lining of the lungs), central nervous system, bones, or disseminated disease (spread throughout the body). Imagine TB as a chameleon, adapting its appearance to blend in with its surroundings. In HIV-infected individuals, TB can

masquerade as various other diseases, making it difficult to recognize. Disseminated TB, characterized by the spread of TB bacteria to multiple organs, is also more common in HIV-infected individuals. This can lead to a wide range of symptoms, depending on the organs involved, making diagnosis even more challenging. It's like a wildfire spreading through the body, leaving a trail of destruction in its wake. In some cases, HIV-infected individuals with TB may present with subtle or non-specific symptoms, such as fatigue, weight loss, or low-grade fever. These symptoms can easily be mistaken for symptoms of HIV itself or other opportunistic infections, potentially leading to delays in diagnosis. It's like a wolf in sheep's clothing, deceiving the observer with its seemingly harmless appearance. The symptoms of TB can also overlap with those of advanced HIV disease, further complicating diagnosis. For example, shortness of breath, cough, and fever can be present in both TB and *Pneumocystis pneumonia* (PCP), a common opportunistic infection in individuals with advanced HIV disease. It's like trying to distinguish between two melodies playing simultaneously, each vying for attention. Sputum smear microscopy and culture, the traditional cornerstones of TB diagnosis, may have reduced sensitivity in HIV-infected individuals, particularly those with low CD4 counts. This is because individuals with advanced HIV disease may have difficulty producing sputum or may have paucibacillary disease, meaning fewer TB bacteria in their sputum. It's like searching for a needle in a haystack, where the needle is smaller and harder to find. In many resource-limited settings, where both TB and HIV are prevalent, access to healthcare can be limited. This can lead to delays in diagnosis and treatment, resulting in poorer outcomes. It's like trying to navigate a maze without a map, where every wrong turn leads to further delays and setbacks. Stigma and discrimination associated with both TB and HIV can prevent individuals from seeking healthcare, further delaying diagnosis and treatment. It's like an invisible wall, preventing individuals from accessing the care they need. Given these challenges,

a high index of suspicion is crucial in diagnosing TB in HIV-infected individuals. Healthcare providers should consider TB in the differential diagnosis of any HIV-infected individual presenting with respiratory symptoms or other symptoms suggestive of TB, even if those symptoms are subtle or non-specific. It's like being a detective, looking for clues and connecting the dots to solve the puzzle. The development of newer diagnostic tools has improved the ability to diagnose TB in HIV-infected individuals. Xpert MTB/RIF, this rapid molecular test offers improved sensitivity compared to sputum smear microscopy and can also detect rifampicin resistance, which is crucial for guiding treatment decisions. It's like having a powerful flashlight that illuminates the path, revealing the hidden clues. Urine LAM Testing, this test detects lipoarabinomannan (LAM), a component of the TB bacteria, in urine. It is particularly useful in diagnosing TB in HIV-infected individuals with low CD4 counts who may have difficulty producing sputum. It's like finding a shortcut through the maze, bypassing the obstacles. Chest X-rays can help identify abnormalities suggestive of TB, such as infiltrates, cavities, or pleural effusions. However, the findings on chest X-ray can be variable in HIV-infected individuals, and further diagnostic testing is usually required. It's like having a bird's-eye view of the maze, providing a general sense of direction but requiring further exploration to find the exit. In the case presented, the patient presented with classic symptoms of pulmonary TB, such as shortness of breath, productive cough, and fever. However, these symptoms could also be attributed to other opportunistic infections or to HIV itself, highlighting the importance of considering TB in the differential diagnosis. The use of Xpert MTB/RIF in this case confirmed the diagnosis of TB and ruled out rifampicin resistance, allowing for the prompt initiation of appropriate treatment. This underscores the value of newer diagnostic tools in improving the diagnosis of TB in HIV-infected individuals.<sup>19,20</sup>

#### 4. Conclusion

This case report presents a complex interplay between tuberculosis (TB) and acquired immunodeficiency syndrome (AIDS), highlighting the severe immune dysfunction that can arise from their co-infection. The patient, a 39-year-old male with a history of suboptimal antiretroviral therapy (ART) adherence, presented with advanced HIV infection characterized by a critically low CD4 count (6 cells/ $\mu$ L) and a reversed CD4:CD8 ratio (0.08). This profound immunosuppression, coupled with active pulmonary TB, underscores the synergistic impact of these two diseases on the immune system. The patient's clinical presentation, laboratory findings, and imaging results collectively paint a concerning picture of advanced disease and immune compromise. His case serves as a stark reminder of the importance of early HIV diagnosis, consistent ART adherence, and comprehensive monitoring to prevent opportunistic infections and disease progression. The severely reversed CD4:CD8 ratio further emphasizes the profound immune dysregulation in this patient and highlights the need for aggressive management to mitigate the risk of further complications. This case underscores the urgent need for integrated TB/AIDS care and prevention strategies, particularly in settings with high prevalence of both infections. By strengthening healthcare systems, improving access to early diagnosis and treatment, and promoting adherence to ART, we can strive to reduce the burden of TB/AIDS co-infection and improve the lives of those affected by these devastating diseases.

#### 5. References

1. Garrido-Rodríguez V, Bulnes-Ramos Á, Olivas-Martínez I, Pozo-Balado MDM, Álvarez-Ríos AI, Gutiérrez F, et al. The persistence of low CD4/CD8 ratio in chronic HIV-infection, despite ART suppression and normal CD4 levels, is associated with pre-therapy values of inflammation and thymic function. *J Microbiol Immunol Infect.* 2024; 57(6): 854–67.
2. Liu B, Zhang Q. Association between CD4 count, CD4/CD8 ratio, and fragility fractures in people living with HIV: a retrospective cohort study in China. *AIDS.* 2024.
3. Ron R, Martínez-Sanz J, Herrera S, Ramos-Ruperto L, Díez A, Sainz T, et al. CD4/CD8 ratio and CD8+ T-cell count as prognostic markers for non-AIDS mortality in people living with HIV. A systematic review and meta-analysis. *Front Immunol.* 2024; 15: 1343124.
4. Wolday D, Kebede Y, Legesse D, Siraj DS, McBride JA, Kirsch MJ, et al. Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade. *PLoS One.* 2020; 15(5): e0233049.
5. Li L, Abudurehman Z, Zhong X, Gong H, Yang F, Awuti A, et al. Clinical symptoms and immune injury reflected by low CD4/CD8 ratio should increase the suspicion of HIV coinfection with tuberculosis. *Heliyon.* 2023; 9(3): e14219.
6. Casado-Fernández G, Cantón J, Nasarre L, Ramos-Martín F, Manzanares M, Sánchez-Menéndez C, et al. Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus. *Front Immunol.* 2024; 15: 1362621.
7. Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. *Lancet HIV.* 2015; 2(3): e98–106.
8. Hewitt A, Freeman MJ, Levenson G, Bailey HH, Carchman E, Striker R, et al. National analysis of over 48,000 veterans with HIV demonstrates CD4/CD8 ratio as a risk

marker for anal intraepithelial lesions and anal cancer. *Dis Colon Rectum*, 2025.

9. Bellissimo F, Pinzone MR, Celesia BM, Cacopardo B, Nunnari G. Baseline CD4/CD8 T-cell ratio predicts prompt immune restoration upon cART initiation. *Curr HIV Res*. 2016; 14(6): 491–6.
10. Figueroa MI, Camiro-Zuñiga A, Belaunzaran-Zamudio PF, Sierra Madero J, Andrade Villanueva J, Arribas JR, et al. The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naïve patients with HIV-infection. *HIV Med*. 2021; 22(4): 254–61.
11. Le LT, Price RW, Gisslén M, Zetterberg H, Emu B, Fabre R, et al. Correlation between CD4/CD8 ratio and neurocognitive performance during early HIV infection. *HIV Med*. 2023; 24(4): 442–52.
12. Shu Y, Zhang M, Li J, Deng X, Liu J, Yang C, et al. Trajectories of CD4 T-cell count, CD8 T-cell count, and CD4/CD8 ratio in patients with HIV and long-term virological suppression based on Yunnan HIV cohort. *HIV Med*. 2024.
13. Caby F, Writing committee of the CD4/CD8 Ratio Working Group of the French Hospital Database on HIV (FHDH-ANRS CO4). CD4/CD8 ratio restoration in long-term treated HIV-1-infected individuals: Incidence and determinants. *AIDS*. 2017.
14. Gao Y, Zhang S, Ou Q, Shen L, Wang S, Wu J, et al. Characterization of CD4/CD8<sup>+</sup> αβ and Vγ2Vδ2<sup>+</sup> T cells in HIV-negative individuals with different *Mycobacterium tuberculosis* infection statuses. *Hum Immunol*. 2015; 76(11): 801–7.
15. Carrère-Kremer S, Kolia-Diafouka P, Pisoni A, Bolloré K, Peries M, Godreuil S, et al. QuantiFERON-TB gold plus assay in patients with latent vs. Active tuberculosis in a low incidence setting: Level of IFN-γ, CD4/CD8 responses, and release of IL-2, IP-10, and MIG. *Front Microbiol*. 2022; 13: 825021.
16. Grinsztejn E, Cardoso SW, Velasque L, Hoagland B, Dos Santos DG, Coutinho C, et al. Impact of latent *M. tuberculosis* infection treatment on time to CD4/CD8 recovery in acute, recent, and chronic HIV infection. *J Acquir Immune Defic Syndr*. 2023; 94(4): 355–63.
17. Wolday D, Kebede Y, Legesse D, Siraj DS, McBride JA, Kirsch MJ, et al. Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade. *PLoS One*. 2020; 15(5): e0233049.
18. Li L, Abudurehman Z, Zhong X, Gong H, Yang F, Awuti A, et al. Clinical symptoms and immune injury reflected by low CD4/CD8 ratio should increase the suspicion of HIV coinfection with tuberculosis. *Heliyon*. 2023; 9(3): e14219.
19. Rashad A, Nafady A, Atia M, Khair A. Tumor necrosis factor-alpha and CD4/CD8 ratio in patients with hypersensitivity pneumonitis. *Egypt J Chest Dis Tuberc*. 2016; 65(3): 689–93.
20. Baruch Baluku J, Musaaazi J, Mulwana R, Bengo D, Sekaggya Wiltshire C, Andia-Biraro I. Sensitivity and specificity of the mean corpuscular volume and CD4/CD8 ratio in discriminating between rifampicin resistant and rifampicin sensitive tuberculosis. *J Clin Tuberc Other Mycobact Dis*. 2020; 21(100205): 100205.